Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Automated Device for Non-Invasive Measurement of Cells’ Electrical Properties to Advance Cancer Diagnosis

By LabMedica International staff writers
Posted on 12 Dec 2023

Effective monitoring of cancer cells is crucial for physicians in guiding treatment and managing the disease, potentially reducing cancer-related mortality. More...

Non-invasive diagnostic platforms that measure the electrical properties of cancer cells show promise for early detection of drug resistance and metastasis in cancer. Earlier studies have found that the type of cancer and its drug resistance status can be understood from cellular permittivity and conductivity data. As a result, there is a growing need for analytical methods that can quickly measure these electrical properties of cells. Electrorotation (ROT) is one method that can capture these cellular properties by analyzing permittivity and conductivity based on how a cell moves in an electric field. This method characterizes cell types and states by profiling their frequency-dependent rotational movement under a modulated electric field. However, traditional ROT methods have limitations, primarily the cumbersome process of capturing, measuring, and replacing cells, which reduces the throughput – the number of cells analyzed over time.

To overcome these challenges, researchers from Tokyo University of Science (TUS, Tokyo, Japan) have developed a continuous flow ROT (cROT) system that incorporates microfluidics to continuously measure cellular dynamics while simultaneously capturing cells on a single device. The researchers designed the device with interdigitating electrodes to induce cell rotation and included a microchannel for cell passage. The geometry of these electrodes enhances the number of cells analyzed and reduces the time needed for cell replacement as measurements are collected. The electric field within the microchannel allows for the analysis of rotational behavior from a continuous flow of cells, boosting the automated system's throughput.

In validation studies, the cROT device significantly outperformed traditional ROT platforms in terms of throughput. While conventional ROT methods process about 10 to 20 cells per hour, the cROT system can handle up to 2700 cells per hour, a more than 100-fold increase. Additionally, it greatly reduces the time needed for cell replacement. Other benefits include the system's high level of automation and its ease of installation or removal. The researchers expect the rapid and accurate analyses enabled by this innovative method to drive significant progress in cancer drug development, diagnostics, and new cell-based therapies. This groundbreaking technology paves the way for collaborations and adoption by key players in the oncology field, potentially transforming cancer treatment strategies.

"With our cROT technique, we've unlocked the ability to delve into the subtle intricacies of single-cell dynamics, including aspects like cell physiology, the state of the cell membrane, and the concentration of intracellular ions," said Dr. Masahiro Motosuke, a Professor in the Department of Mechanical Engineering at TUS and the project's Principal Investigator.

Related Links:
TUS


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Slide Scanner System
NanoZoomer S540MD
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.